Hamilton, Danilov join City of Hope

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stanley Hamilton, formerly of MD Anderson Cancer Center, was named chair of the Department of Pathology at City of Hope, and Alexey Danilov was named associate director of City of Hope’s Toni Stephenson Lymphoma Center.

Hamilton said his goal is to bring access to state-of-the-art specialized pathology to every patient at every City of Hope satellite center, as well as improving and enhancing the biomarker data used in clinical trials, and further integrating digital pathology into the overall informatics of the institution.

Danilov brought his independently-funded lab to City of Hope’s Toni Stephenson Lymphoma Center. Danilov researches treatment of chronic lymphocytic leukemia and many forms of lymphoma.

Danilov is focused on identifying cell proteins—some that promote cancer growth, some that inhibit it—learning how they deteriorate, and finding drugs that can affect the process.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login